Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTR004 PET MPI in CAD Diagnosis
NCT05885841Phase 2Completed
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Feb 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 18F-FMPP in coronary artery disease (CAD), sponsored by Sinotau Pharmaceutical Group. Started Feb 2022; status: completed.
02
Drugs
18F-FMPP
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05885841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05885841.